HOUSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE: EGY, LSE: EGY) (“Vaalco” or the “Company”) announced that it will be participating in SpareBank 1 Markets Energy Conference to be held in Oslo, Norway where Chief Executive Officer George Maxwell is scheduled to make a presentation on Wednesday, February 25, 2026. In conjunction with this press release, the Company has posted an updated investor presentation to its website. The presentation is available at the following link: (https://www ...

CINCINNATI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO” or the “Company”), one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers, today announced that its operating partnership, Phillips Edison Grocery Center Operating Partnership I, L.P. (the “Operating Partnership”), has priced a public offering of $350 million aggregate principal amount of 4.750% senior unsecured notes due 2033 (the “Notes”). The Notes ...

Net Income per Diluted Share of $0.99 for the Fourth Quarter and $10.84 for the Full Year of 2025 Core FFO per Share of $1.40 for the Fourth Quarter and $6.68 for the Full Year of 2025 North America Same Property NOI increased by 7.9% for the Fourth Quarter and 5.7% for the Full Year of 2025 Acquired 14 MH and RV Communities for $457.0 million and Distributed Over $1.5 Billion of Capital to Shareholders, Inclusive of Cash Distributions and Share Repurchases in 2025 Establishing Guid ...

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that management will participate at the 46th Annual TD Cowen Healthcare Conference, taking place March 2-4, 2026 in Boston, MA. 46th A ...

SINGAPORE, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Antalpha Platform Holding Company (NASDAQ: ANTA) ("Antalpha" or the "Company"), a leading institutional digital asset financing platform, today announced that it will report its financial results for the fourth quarter and full year 2025 before the U.S. market open on March 3, 2026. The Company’s management team will hold a conference call at 8:00 A.M. U.S. Eastern Time on March 3, 2026 (or 9:00 P.M. Singapore Time on March 3, 2026) to discuss the financial resul ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Inspired Entertainment, Inc. ("Inspired" or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware and services, announced that it will report financial results for the fourth quarter and full year ended December 31, 2025 before the market opens on Tuesday, March 10, 2026. Inspired management will host a conference call and simultaneous webcast the same day at 8:30 a.m. ET / 12:30 p.m. in the UK to discuss the Company's resul ...

Core Insights - Cardiff Oncology reported positive results from the Phase 2 CRDF-004 trial for first-line RAS-mutated metastatic colorectal cancer (mCRC), showing a robust objective response rate (ORR) of 72.2% with the 30 mg onvansertib + FOLFIRI/bev combination, compared to 43.2% with standard of care (SoC) [1][5] - The trial also demonstrated a significant improvement in progression-free survival (PFS) with a hazard ratio (HR) of 0.37, indicating a strong potential for onvansertib to enhance patient outcomes [1][5] - The company plans to advance the 30 mg dose of onvansertib into a registrational program, with detailed data and plans expected in the first half of 2026 [1][2] Clinical Development - The CRDF-004 trial results indicate a consistent, dose-dependent treatment benefit, with nearly a 30% improvement in response rate over the control arm and encouraging durability trends in PFS [2][5] - The company has not observed significant added toxicity with the 30 mg onvansertib dose in combination with FOLFIRI/bev, supporting its advancement into registrational development [5] Financial Performance - For the year ended December 31, 2025, Cardiff Oncology reported total operating expenses of approximately $49.6 million, a slight increase from $49.3 million in 2024, primarily due to higher selling, general, and administrative expenses [8][14] - The company reported a net loss of $45.876 million for 2025, compared to a net loss of $45.455 million in 2024, with a net loss per common share of $0.69 [14] - As of December 31, 2025, Cardiff had approximately $58.3 million in cash and cash equivalents, sufficient to fund operations into the first quarter of 2027 [7] Leadership Changes - In January 2026, Cardiff announced executive leadership changes to support its transition into late-stage clinical development, appointing Mani Mohindru as interim Chief Executive Officer [4] - The company is actively searching for a permanent Chief Executive Officer and Chief Financial Officer to strengthen its leadership team [4]

Company Overview - Teva Pharmaceutical Industries Ltd. is transforming into a leading innovative biopharmaceutical company, supported by a world-class generics business [3] - The company has a commitment to improving health for over 120 years, focusing on neuroscience, immunology, complex generic medicines, biosimilars, and pharmacy brands globally [3] Upcoming Events - Richard Francis, Teva's President and CEO, will participate in several investor conferences in March 2026, including the UBS European Healthcare Conference on March 3, the Leerink Partners Global Healthcare Conference on March 9, and the Barclays 28th Annual Global Healthcare Conference on March 10 [1][6] - Live webcasts of the presentations will be available on Teva's Investor Relations website, with archived versions accessible for 30 days after the events [2][1]

NEWBURYPORT, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), a contract development and manufacturing organization that specializes in single-use and single-patient medical devices, today reported 2025 net income of $68.3 million, 15.8% higher than net income of $59.0 million for 2024. Adjusted net income grew 12.7% to $76.1 million. Net sales for the year ended December 31, 2025 were $602.8 million, 19.5% higher than 2024 sales of $504.4 million. GAAP and adjusted earnings p ...

Company Overview - Art Technology Acquisition Corp. is a blank check company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses [1] - The company may pursue acquisition opportunities in any business or industry or at any stage of its corporate evolution, with a primary focus on technology, art, financial services, and investment banking sectors [1] Trading Information - Starting February 27, 2026, holders of units sold in the initial public offering can elect to separately trade the Company's Class A ordinary shares and warrants [1] - The Class A ordinary shares and warrants will trade on the Nasdaq Global Market under the symbols "ARTC" and "ARTCW," respectively, while units not separated will continue to trade under the symbol "ARTCU" [1] Leadership - The company is led by Daniel G. Cohen, who serves as Chairman and Chief Executive Officer, and Katherine Fleming, who is the Vice Chairman [1]